ELICIT PLANT, the Future World Champion That Helps the Field Crop Industry Tackle Water Stress and Scarcity
One year after joining the French Tech Agri 20 program, Agri-tech company ELICIT PLANT has joined the circle of the 100 most strategic and innovative French companies for France by 2030, as part of the French Tech 2030 program.
Following a rigorous selection process led by the French General Secretariat for Investment – the body in charge of the France 2030 program – with the help of all French government departments and Bpifrance, ELICIT PLANT, a pioneering company at the forefront of the fight against the impact of climate change on agriculture, and in particular on field crops (corn, wheat, soy and sunflower), has made a striking entrance into the first edition of the French Tech 2030 program.
The initiative aims to provide great public support to one hundred or so innovative companies, in a context of highly aggressive international competition, so as to position them as world leaders by 2030, by providing:
- Financial support, provided by France 2030 operators,
- Extra-financial support measures: export, business opportunities, global economic influence strategy, increased visibility.
This announcement adds to the legitimacy of the track record and international development of ELICIT PLANT, the developer of the first phytosterol-based ecological innovation for the agricultural industry, the only widely available technology scale that allows for significant field crop yield gains in an increasingly critical climatic context.
Several French departements are being affected by drought even before the start of the summer season, leaving public authorities no other option but to impose water restrictions in certain areas. The risk of drought is now accepted as fact in a number of regions. This is cause for concern among scientists, who fear that the summer of 2023 will be even more difficult than 2022.
ELICIT PLANT, the biotech that pioneers phytosterols to help the field crop industry combat water stress
The flagship BEST-a product designed for corn production reduces water consumption by up to 20%, and is in high demand in France, Brazil and Ukraine, with over 100 cooperative customers.
In 2023, the ELICIT PLANT innovation will be distributed to 100 coops and distributors, addressing a total potential of 100,000 corn growers and 10 million hectares of corn in France, Brazil and Ukraine.
ELICIT PLANT has created at the heart of its open-field laboratory based in Moulins-sur-Tardoire a technological platform called EliTerra® that will enable the company to develop new products designed for the culture of wheat and barley in Europe, of sunflower in Ukraine and of soybeans for the Brazilian market. Marketing authorization applications are also underway in the United States.
“We are very proud to join the French Tech 2030 program, Jean-François Déchant, Co-founder and CEO of ELICIT PLANT comments. Our mission is to help the field crop industry everywhere in the world address climate change. The French Tech 2030 project will accelerate our development in France and in the world (Brazil, Ukraine and North America). There is an urgent need to provide innovative solutions to growers, and we are proud to be able to contribute effectively to the necessary agricultural transition with high-performance, reliable products that respect our environment."
About Elicit Plant:
Elicit Plant is an agri-biotech company whose ambition is to become the champion of the ecological transition for agriculture and respond to the global challenges of the impact of climate change on row crops. EliTerra®, Elicit Plant's proprietary technology, is based on the exogenous contribution of phytosterols, a set of molecules of plant origin, which increases the resistance of plants to stress by eliciting their natural defenses. Large-scale field trials - more than 500 trials on 3 continents - have demonstrated that the biosolutions from the Eliterra® Platform are the only ones offering farmers a regular and sufficient return on investment for use on field crops, with an average yield gain of 12%. In 2022, Elicit Plant began marketing its BEST-a product line in France, particularly for corn crops, and has obtained marketing authorizations for Ukraine, Brazil and Europe. For more information: www.elicit-plant.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230620520000/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom